Abiopharma

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

Alterity Therapeutics Limited (ATHE) Files Form 6-K

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BRAINSWAY (BWAY) Files Form 6-K

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

GSK plc (GLAXF) Files Form 6-K

(90% Positive) MONTE ROSA THERAPEUTICS, INC. (GLUE) Provides Update on development for today at 8 a